Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
J Cell Mol Med. 2019 Nov;23(11):7617-7631. doi: 10.1111/jcmm.14635. Epub 2019 Sep 26.
Exosomes are served as substitutes for stem cell therapy, playing important roles in mediating heart repair during myocardial infarction injury. Evidence have indicated that lipopolysaccharide (LPS) pre-conditioning bone marrow-derived mesenchymal stem cells (BMSCs) and their secreted exosomes promote macrophage polarization and tissue repair in several inflammation diseases; however, it has not been fully elucidated in myocardial infarction (MI). This study aimed to investigate whether LPS-primed BMSC-derived exosomes could mediate inflammation and myocardial injury via macrophage polarization after MI. Here, we found that exosomes derived from BMSCs, in both Exo and L-Exo groups, increased M2 macrophage polarization and decreased M1 macrophage polarization under LPS stimulation, which strongly depressed LPS-dependent NF-κB signalling pathway and partly activated the AKT1/AKT2 signalling pathway. Compared with Exo, L-Exo had superior therapeutic effects on polarizing M2 macrophage in vitro and attenuated the post-infarction inflammation and cardiomyocyte apoptosis by mediating macrophage polarization in mice MI model. Consequently, we have confidence in the perspective that low concentration of LPS pre-conditioning BMSC-derived exosomes may develop into a promising cell-free treatment strategy for clinical treatment of MI.
外泌体可作为干细胞治疗的替代品,在介导心肌梗死后的心脏修复中发挥重要作用。有证据表明,脂多糖(LPS)预处理骨髓间充质干细胞(BMSCs)及其分泌的外泌体可促进几种炎症疾病中的巨噬细胞极化和组织修复;然而,在心肌梗死(MI)中尚未完全阐明。本研究旨在探讨 LPS 预处理的 BMSC 衍生外泌体是否可以通过 MI 后的巨噬细胞极化来介导炎症和心肌损伤。在这里,我们发现 LPS 刺激下,来自 BMSC 的外泌体(Exo 和 L-Exo 组)均增加了 M2 巨噬细胞的极化,减少了 M1 巨噬细胞的极化,强烈抑制了 LPS 依赖性 NF-κB 信号通路,并部分激活了 AKT1/AKT2 信号通路。与 Exo 相比,L-Exo 在体外对 M2 巨噬细胞的极化具有更好的治疗效果,并通过调节巨噬细胞极化减轻了小鼠 MI 模型中的梗死后炎症和心肌细胞凋亡。因此,我们有信心认为,低浓度 LPS 预处理的 BMSC 衍生外泌体可能成为一种有前途的无细胞治疗策略,用于 MI 的临床治疗。
Stem Cell Res Ther. 2019-11-26
J Funct Biomater. 2025-4-23
Front Cardiovasc Med. 2025-4-28
J Cell Mol Med. 2025-4
Adv Sci (Weinh). 2025-5
J Nanobiotechnology. 2025-3-18
J Cardiovasc Transl Res. 2018-9-19
Stem Cells Int. 2018-7-24
Biochem Biophys Res Commun. 2018-8-17
Cell Physiol Biochem. 2018
J Cardiovasc Transl Res. 2018-3-10